跳至主要内容
临床试验/JPRN-jRCT2080221611
JPRN-jRCT2080221611未知1 期

A Phase I/II study of NK012 in patients with multiple myeloma

ippon Kayaku Co., Ltd.0 个研究点目标入组 60 人开始时间: 2011年10月7日最近更新:
适应症

试验速览

阶段
1 期
发起方
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
>= 20age old 至 <= 79age old(—)
性别
All

入选标准

  • 1.Symptomatic disease thought to require therapy and received therapy at least 2 regimens
  • 2.ECOG performance status (P.S.) score of 0-2(include P.S.3 with osteolytic disease)
  • 3.Patients who don't have abnormal ECG with therapy
  • 4.Patients age 20 to 79 years(inclusive)at time of informed consent

排除标准

  • 1.By pharmacogenetic testing, patients who are homozygous for UGT1A1*28 or UGT1A1*6, or those who are simultaneously heterozygous for UGT1A1*28 and UGT1A*6
  • 2.Patients who received irinotecan hydrochloride or nogitecan hydrochloride or drugs (include investigational agent) which have same mechanisms of action (type I DNA topoisomerase inhibition)
  • 3.Patients who are plasma cell leukemia
  • 4.Patients who have active infection

研究者

发起方
ippon Kayaku Co., Ltd.

相似试验